Auris Medical Holding

US: EARS

$9m market cap

$0.4 last close

Auris Medical is a Swiss biopharmaceutical company developing neurotology therapeutics. The company is developing intranasal betahistine in a Phase I trial for mental disorder supportive care and is entering Phase II for vertigo; both are designed to demonstrate proof-of-concept.

Investment summary

Auris Medical Holding announced in July that the 50-subject AM-201 Phase Ib trial for olanzapine-induced weight gain and somnolence completed enrolment, with top-line data in five dose levels expected in the coming weeks. Due to the positive safety profile seen in the trial so far (efficacy is unknown as the company is blinded), the company is seeking to extend the trial by adding two higher dose cohorts, with data from these expected around Q120. The company has also initiated the 138-patient AM-125 Phase II trial in acute vertigo, with data expected around Q419/Q120.

Y/E Dec
Revenue (CHFm)
EBITDA (CHFm)
PBT (CHFm)
EPS (CHFc)
P/E (x)
P/CF (x)
2017A 0.0 (24.5) (25.9) (1072.03) N/A N/A
2018A 0.0 (11.0) (12.0) (1532.81) N/A N/A
2019E 0.0 (11.0) (11.0) (377.63) N/A N/A
2020E 0.0 (17.9) (18.8) (426.39) N/A N/A
Last updated on 14/03/2019
Industry outlook

Acute vertigo/dizziness is one of the most common causes of visits to the emergency room with roughly 2.6m visits associated with the condition each year.

Last updated on 14/03/2019
Sector
Healthcare
Share price graph
Balance sheet
Forecast net debt (CHFm) 1.1
Forecast gearing ratio (%) 51
Price performance
%
1m
3m
12m
Actual 1.9 (15.1) (43.8)
Relative* 6.0 (15.5) (44.7)
52-week high/low US$2.0/US$0.2
*% relative to local index
Key management
Thomas Meyer CEO
Hernan Levett CFO